Kevin Yang ⎜Sep 12, 2018 ⎜ Industry
This first-in-human study demonstrated that 177Lu-EB-PSMA-617 had higher accumulation in mCRPC and that low imaging dose appears to be effective in treating tumors with high 68Ga-PSMA-617 uptakes. Elevated uptakes of 177Lu-EBPSMA-617 in kidneys and red bone marrow were well tolerated at the administered low dose. Further investigations with increased dose and frequency of administration are warranted.
Jie Zang & Xinrong Fan & Hao Wang & Qingxing Liu & Jingnan Wang & Hui Li & Fang Li & Orit Jacobson & Gang Niu & Zhaohui Zhu & Xiaoyuan Chen
Info on purchasing Lu-177, please contact email@example.com.
Kevin Yang ⎜Sep 6, 2018 ⎜ Industry
Prostate cancer is the most frequently diagnosed malignant tumor in men worldwide. Prostate-specific membrane antigen (PSMA) is a surface molecule specifically expressed by prostate tumors and has been shown to be a valid target for internal radionuclide therapy in both preclinical and clinical settings. The most common radiotherapeutic agent is the small molecule 177Lu-PSMA-617, (more…)
Patricia Acton ⎜Sep 5, 2018 ⎜ Calendar
isoSolutions will be attending the United Pharmacy Partners (UPPI, LLC) 2018 Annual Meeting to be held in San Antonio, TX September 12 to 15, 2018. (more…)
Tags: Batch Reporting System Beta detection Beta flow monitor Beta radio-detector Cassette-based synthesis Chromatography Software Clarity Elysia-raytest Ga-68 synthesis Gamma detection Gamma flow monitor Gamma radio-detector Gamma spectroscopy Gas Chromatography GC systems HPLC isoSolutions LIMS Liquid Scintillation Liquid Scintillation Pump Lu-177 MCA Multichannel analyzer North America Nuclear Medicine PET QC QC-Cubicle Quality Control Radio Detector Radio nuclide identification Radio nuclide purity radio spectroscopy radio TLC scanners radio-flow monitor radio-HPLC radio-synthesis radio-TLC Systems Radio-tracer Radiopharmaceutical Tracer Radiopharmaceuticals Radiopharmacy Residual Solvents Control Single-use cassette synthesis SPECT QC Spectroscopy Software Sterile filter integrity test Sterility Filter Test Synthesis Modules Synthesizers Tradeshows UPPI
Kevin Yang ⎜Jul 26, 2018 ⎜ Industry
Y-90 radioembolization for HCC patients with PVT appears to have an acceptable safety profile, with better survival in CP-A patients than in CP-B patients. This study confirms prior reports of survival in PVT patients treated with Y-90 radioembolization, and survival after Y-90 radioembolization appears to exceed that in
similar patients treated with systemic therapies. Despite the negative studies recently reported, Y-90 radioembolization is a reasonable treatment option in properly selected PVT patients. Further controlled studies are needed to compare it with systemic therapies or other locoregional treatments for advanced-stage HCC.
Nadine Abouchaleh1, Ahmed Gabr1, Rehan Ali1, Ali Al Asadi1, Ronald A. Mora1, Joseph Ralph Kallini1, Samdeep Mouli1, Ahsun Riaz1, Robert J Lewandowski1, and Riad Salem1–3
Info on purchasing Y-90, please contact firstname.lastname@example.org
Read the full article PDF
Hans Peng ⎜Jul 11, 2018 ⎜ Industry
isoSolutions Marketing and Management will send its representative in China, Eric Huang to the 19th China Cardiovascular and Nuclear Medicine Annual meeting organized by Chinese Society of Nuclear Medicine (http://www.csnm.com.cn/) in Sichuan, China.
The 19th China Cardiovascular and Nuclear Medicine Annual Meeting will be held in Chengdu, Sichuan from July 12 to July 15, 2018. The meeting will focus on the progress of diagnosis and treatment of nuclear medicine in China, the clinical trial of imaging medicine and nuclear medicine. Also its applications and advances in related fields such as cancer, cardiovascular, neurology, etc.
The conference will also discuss the reports and hot topics PET/CT and molecular imaging clinical applications and radionuclide treatment; the conference has invited experts from clinical disciplines and imaging disciplines. they will conduct a wide range of communication and discussion on how to improve the diagnostic and therapeutic level of imaging medicine and nuclear medicine, promote the clinical work of imaging medicine and nuclear medicine, promote and popularize the clinical application of imaging medicine and nuclear medicine.
We sincerely hope that relevant medical and scientific personnel from all over the country will participate in the conference. In order to strengthen the communication between imaging and clinical subjects, we will promote the development of imaging medicine and nuclear medicine in China.
We especially look forward to experts in internal medicine, surgery, radiology, ultrasound and nuclear medicine. For more info: http://www.csnm.com.cn/special/65
David T. Drummond ⎜Jun 29, 2018 ⎜ Industry
PHILADELPHIA (Embargoed until 6:30 p.m. EDT, Tuesday, June 26, 2018) – In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to radionuclide therapy targeting prostate specific membrane antigen (PSMA) with the radionuclide lutetium-177 (177Lu). At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), researchers reported on a phase II prospective trial. Using gallium-68 (68Ga)-PSMA11 positron emission tomography (PET) imaging, men who had exhausted conventional therapies were screened. Those with high PSMA-expression proceeded to 177Lu-PSMA617 (LuPSMA) therapy and experienced high response rates, which is clearly demonstrated in the PSMA PET imaging figure selected as the 2018 SNMMI Image of the Year.
Each year, SNMMI chooses an image that exemplifies the most promising advances in the field of nuclear medicine and molecular imaging. The state-of-the-art technologies captured in these images demonstrate the capacity to improve patient care by detecting disease, aiding diagnosis, improving clinical confidence and providing a means of selecting appropriate treatments. This year, the SNMMI Henry N. Wagner, Jr., Image of the Year was chosen from more than 2,200 abstracts submitted to the meeting and voted on by reviewers and the society leadership.
The 2018 Image of the Year goes to a team of researchers at the Peter MacCallum Cancer Centre in Melbourne, Australia. The image demonstrates exceptional responses in a series of patients who received LuPSMA therapy after other treatments stopped working. In each patient, the extent of tumor spread before and after treatment is visualized with clarity using PSMA PET. These patients experienced improved quality of life, including reduction of pain, and correlated with marked reduction of prostate specific antigen (PSA), a blood tumor marker.
“This work reflects an appreciation for all the basic science and translation work that has been performed by many groups over a long period of time to develop prostate-specific membrane antigen (PSMA) theranostics as a paradigm-changing practice for improving patient outcomes,” explained Professor Michael Hofman of the Peter MacCallum Cancer in Melbourne, Australia. “These images tell a story about exceptional responses observed in patients who had progressed after standard therapies. They match striking improvements in patient quality of life. With further research, we look forward to seeing nuclear medicine evolve as a key specialty and standard-of-care in cancer management.” He added, “I would also like to extend thanks to ANSTO, Australia’s producer of no-carrier-added Lutetium-177, and Endocyte, which produces PSMA; they helped make this study possible.”
Umar Mahmood, MD, PhD, chair of the SNMMI Scientific Program Committee, noted, “The last decade has seen a blossoming of theranostics to treat tumors with molecularly-guided radiotherapy. The expansion of patients benefiting from this approach is remarkable, and it is wonderful to know that this effort is being led by nuclear medicine physicians and scientists.”
Mahmood stated, “Prostate cancer, which affects millions of men around the world, can be painful and deadly in the metastatic setting. This phase II prospective study by Michael Hofman and colleagues clearly shows the benefit to men with castrate-resistant prostate cancer treated with a beta emitter targeting PSMA when their tumors expressed PSMA. It is gratifying to see the benefit of the approach both rigorously and objectively demonstrated in this trial, in terms of improvement in disease burden and improvement in the pain severity the men suffered.”
Abstract 531: “High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial,” Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.
Kevin Yang ⎜Jun 6, 2018 ⎜ Industry
A positive response for surrogate parameters demonstrates remarkable antitumor activity for 225Ac-PSMA-617. Swimmer-plot analysis indicates a promising duration of tumor control, especially considering the unfavorable prognostic profile of the selected advanced-stage patients. Xerostomia was the main reason patients discontinued therapy or refused additional administrations and was in the same dimension as nonresponse; this finding indicates that further modifications of the treatment regimen with regard to side effects might be necessary to further enhance the therapeutic range.
Clemens Kratochwil1, Frank Bruchertseifer2, Hendrik Rathke1, Markus Hohenfellner3, Frederik L. Giesel1, Uwe Haberkorn*1,4, and Alfred Morgenstern*2
Info on purchasing Ac-225, please contact email@example.com .
David T. Drummond ⎜May 7, 2018 ⎜ Industry
The Armstrong-Lepeska Science Marketing Scholarship, sponsored by isoSolutions, has been awarded to two more students. This scholarship is granted to a student at Langara College in Vancouver. To highlight the importance of marketing and sales of high-technology, scientifically-intensive products, the scholarship awards a student in a scientific discipline who completes a course in Marketing.
David T. Drummond ⎜Jan 19, 2018 ⎜ Calendar
2018 June 23 to 26 @ Pennsylvania Convention Center, Headquarter Hotel: Philadelphia Marriott
isoSolutions is pleased to inform you that we will attend the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). You can find us at Booth 1001 in the Pennsylvania Convention Center. We hope to see you there and we can arrange a time and place to meet if you wish.
We look forward to seeing you in Philadelphia, Pennsylvania.
David T. Drummond ⎜Jan 19, 2018 ⎜ Calendar
isoSolutions will be present at the Canadian Nuclear Medicine Annual Scientific Meeting in Vancouver, BC from 2018–03–23 to
More info about the event on canm-acmn.ca
David T. Drummond ⎜Nov 3, 2017 ⎜ Company
Mr. Gabriel Freitas has been appointed as the Customer Service Manager for isoSolutions. This new position provides general administrative support to the team, with primary responsibility for customer and supplier support. The main responsibilities of this position are to maintain the order desk and customer support.The Customer Service Manager will prepare quotations; receive, enter, acknowledge and distribute purchase orders and invoices; check and distribute shipping documents; process order changes; and correspond with suppliers, customers and sales managers regarding orders and new product requests. Other duties will include organizing tradeshows and logistics for tradeshows; coordinating website maintenance; preparing and distributing newsletters; managing promotional brochures; and assisting with staff training programs. (more…)
David T. Drummond ⎜Mar 29, 2017 ⎜ Industry
The Armstrong-Lepeska Science Marketing Scholarship, sponsored by isoSolutions, has been awarded to two more students.
This scholarship is granted to a student at Langara College in Vancouver. To highlight the importance of marketing and sales of high-technology, scientifically-intensive products, the scholarship awards a student in a scientific discipline who completes a course in marketing. This year, two students were funded: Mr. Hazhir Goodarznia and Mr. Adrian Wong (more…)
David T. Drummond ⎜Dec 27, 2016 ⎜ Company
To reflect additions to our product line and expansion of our business, isoSolutions will install a new, updated web site early in 2017. The new web site will incorporate new features that will be of interest to our visitors and will help our clients and partners to find the information they are seeking.
The new web site will be designed and installed by Mr. Bruno Tomazelli, who has joined our team. Bruno is a graphic designer with over five years of experience in advertising. (more…)
David T. Drummond ⎜Nov 1, 2016 ⎜ Calendar
isoSolutions will be present at the Brazilian Nuclear Medicine Congress from 2016–11–12 to 2016–11–14.
David T. Drummond ⎜Oct 25, 2016 ⎜ Calendar
isoSolutions will be present at the Canadian Nuclear Medicine Annual Scientific Meeting in Halifax, Nova Scotia from 2016–04–21 to 2016–04–24.
David T. Drummond ⎜Sep 1, 2016 ⎜ Calendar
isoSolutions will be present at the XXV ALASBIMN Congress in Punta del Este, Uruguay from 2015–11–18 to 2015–11–21.
David T. Drummond ⎜Jun 1, 2016 ⎜ Calendar
The annual meeting of the Society of Nuclear Medicine and Medical Imaging (SNNMI) will be held in Vancouver, Canada from 08 June to 12 June 2013. isoSolutions Marketing & Management Inc. will be exhibiting a wide range of nuclear medicine products.
isoSolutions is presenting a package of products and services for diagnostic and therapeutic radiolabeling applications — a complete labeling solution. isoSolutions can provide a complete range of radioisotopes, including a Ga-68 Generator (iThemba), Lu-177, Y-90, Re-188 and I-131. These products are complemented by a state-of-the-art automated labeling module (Trasis All-in-One) and a complete range of labeling peptides. Finally, expert, experienced consulting services are offered for radiochemistry, licensing (preparation of CMC sections, INDs, DMFs) and grant applications.
isoSolutions also offers an extensive catalog of radiochemicals, radiopharmaceuticals, in-vivo cold kits, stable isotopes, labeled compounds, reagents, shipping containers, laboratory equipment and calibration sources from high quality, reliable suppliers. With isoSolutions, customers can obtain a one-stop shopping service as well as technical support.
David T. Drummond, Managing Director of isoSolutions, states, “We are looking forward to welcoming our customers from North America, South America, China and elsewhere to our booth #1336 at the SNNMI exhibition. We are especially proud that this international congress is being held in our hometown of Vancouver.”